Systematic review of pharmacoeconomic models for schizophrenia

about

Systematic review of pharmacoeconomic models for schizophrenia

Item

http://www.wikidata.org/entity/Q57169493

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Systematic review of pharmacoeconomic models for schizophrenia

@en

Systematic review of pharmacoeconomic models for schizophrenia

@nl

type

Item

label

Systematic review of pharmacoeconomic models for schizophrenia

@en

Systematic review of pharmacoeconomic models for schizophrenia

@nl

prefLabel

Systematic review of pharmacoeconomic models for schizophrenia

@en

Systematic review of pharmacoeconomic models for schizophrenia

@nl

P1476

Systematic review of pharmacoeconomic models for schizophrenia

@en

P2093

Aurélie Millier

http://www.w3.org/2001/XMLSchema#string

Junwen Zhou

http://www.w3.org/2001/XMLSchema#string

Mondher Toumi

http://www.w3.org/2001/XMLSchema#string

P2860

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States.

Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data.

Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2.

Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.

A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss

Choosing cost-effective interventions in psychiatry: results from the CHOICE programme of the World Health Organization

Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison

P304

1508272

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/20016689.2018.1508272

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30128087

http://www.w3.org/2001/XMLSchema#string

P921

schizophrenia

P932

6095033

http://www.w3.org/2001/XMLSchema#string